Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 144
interventional 114
Observational 27
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Biological|placebo 64
Biological 30
Drug|placebo 5
Other 4
Drug 3
Biological|Other 2
Other|Procedure 2
Biological|Device 1
Diagnostic Test 1
placebo 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 51
Thailand 8
Brazil 5
Australia 4
Mexico 4
Singapore 4
Malaysia 3
Puerto Rico 3
Brazil|Colombia|Honduras|Mexico|Puerto Rico 2
Colombia 2
India 2
Philippines 2
Taiwan 2
Vietnam 2
Bangladesh 1
Brazil|Colombia|Dominican Republic|Nicaragua|Panama|Philippines|Sri Lanka|Thailand 1
Cambodia 1
Colombia|Honduras|Mexico|Puerto Rico 1
Colombia|Peru 1
Colombia|Philippines 1
Colombia|Puerto Rico|Singapore|Thailand 1
Dominican Republic|Panama|Philippines 1
France 1
Indonesia 1
Indonesia|Malaysia|Philippines|Thailand|Vietnam 1
Malaysia|Philippines|Thailand 1
Malaysia|Singapore 1
NA 1
Peru 1
Réunion 1
Sri Lanka 1
Thailand|Venezuela 1
United Kingdom 1
United States|Mexico 1

Sites per Study

Site_count Study_Count
1 59
2 18
3 11
4 5
5 6
7 3
8 2
9 1
10 2
11 2
12 1
14 1
16 1
22 1
28 1

Phase

Phase Study_Count
Phase 1 48
Phase 2 33
Phase 3 18
N/A 10
Phase 1/Phase 2 5

Number of Arms

Number_of_Arms Count_of_Studies
1 11
2 55
3 18
4 17
5 7
6 3
7 1
10 1
13 1

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3
Min. 10.00 9.0000 7 24.0000 84.000
1st Qu. 53.25 24.7500 7 118.0000 420.000
Median 357.00 48.0000 50 210.0000 717.500
Mean 1404.40 54.4375 51 452.2424 4229.722
3rd Qu. 1764.25 74.0000 51 360.0000 918.000
Max. 7979.00 160.0000 140 4002.0000 20869.000

Trial Group Type

group_type Group_Count
Experimental 237
Placebo Comparator 68
Active Comparator 11
Other 5
Sham Comparator 3
No Intervention 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 98
Single Group Assignment 14
Sequential Assignment 2

Primary Purpose

primary_purpose Study_Count
Prevention 94
Treatment 10
Other 4
Basic Science 3
Diagnostic 2
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 3
Cambodia 2
Malaysia 2
Taiwan 2
Thailand 2
Bangladesh|Brazil|Cambodia|El Salvador|Indonesia|Malaysia|Venezuela|Vietnam 1
Brazil 1
Brazil|Colombia|Mexico|Puerto Rico 1
Brazil|Mexico 1
France|French Guiana|Guadeloupe|Martinique 1
India 1
Indonesia|Malaysia|Philippines|Thailand|Vietnam 1
Mexico 1
NA 1
Nepal 1
Philippines 1
Puerto Rico 1
Singapore 1
United States|El Salvador 1
United States|Puerto Rico 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 14
2 3
3 1
4 3
6 1
8 1
9 1
11 1
18 1
19 1

Enrollment Metrics

Measure Observational
Min 34.00
1st Qu 328.00
Median 775.00
Mean 16755.93
3rd Qu 5307.00
Max 182353.00

Observation Model

observational_model Study_Count
Cohort 17
Case-Control 4
Case-Only 4
Case Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 21
Retrospective 3
Cross-Sectional 1
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
Colombia 2
Taiwan 1

Sites per Study

Site_count Study_Count
1 2
8 1

Enrollment Metrics

Measure Registries
Min 500
1st Qu 535
Median 570
Mean 1090
3rd Qu 1385
Max 2200

Registry Model

observational_model Study_Count
Case-Control 2
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
1 Day 2
4 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT02824198 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule https://ClinicalTrials.gov/show/NCT02824198 Completed Sanofi 2017-03-18
NCT04350905 Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia https://ClinicalTrials.gov/show/NCT04350905 Recruiting National Institutes of Health Clinical Center (CC) 2022-02-28
NCT02450838 Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) https://ClinicalTrials.gov/show/NCT02450838 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-10-31
NCT01782300 Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart https://ClinicalTrials.gov/show/NCT01782300 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-03-31
NCT02021968 Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT02021968 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-03-31
NCT03341637 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) https://ClinicalTrials.gov/show/NCT03341637 Completed Takeda 2019-01-26
NCT02993757 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® https://ClinicalTrials.gov/show/NCT02993757 Completed Sanofi 2019-05-27
NCT02992418 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects https://ClinicalTrials.gov/show/NCT02992418 Completed Sanofi 2019-11-28
NCT02979535 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® https://ClinicalTrials.gov/show/NCT02979535 Completed Sanofi 2019-03-25
NCT02879266 Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age https://ClinicalTrials.gov/show/NCT02879266 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-09-07
NCT02873260 Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30 https://ClinicalTrials.gov/show/NCT02873260 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-11-30
NCT02833584 Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults https://ClinicalTrials.gov/show/NCT02833584 Completed Phramongkutklao College of Medicine and Hospital 2017-12-31
NCT02747927 Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children https://ClinicalTrials.gov/show/NCT02747927 Active, not recruiting Takeda 2018-07-11
NCT02684383 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine https://ClinicalTrials.gov/show/NCT02684383 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-07-31
NCT02678455 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh https://ClinicalTrials.gov/show/NCT02678455 Active, not recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-02-29
NCT02628444 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age https://ClinicalTrials.gov/show/NCT02628444 Active, not recruiting Sanofi 2020-06-30
NCT02623725 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule https://ClinicalTrials.gov/show/NCT02623725 Completed Sanofi 2016-11-23
NCT02570152 A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia https://ClinicalTrials.gov/show/NCT02570152 Completed GlaxoSmithKline 2019-06-28
NCT04422782 New Tools for Predicting Capillary Leak Shock During Dengue Fever https://ClinicalTrials.gov/show/NCT04422782 Active, not recruiting Centre Hospitalier de Cayenne 2022-05-14
NCT02741128 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults https://ClinicalTrials.gov/show/NCT02741128 Active, not recruiting Sanofi 2022-06-30
NCT02433652 Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 https://ClinicalTrials.gov/show/NCT02433652 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-11-30
NCT02421367 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults https://ClinicalTrials.gov/show/NCT02421367 Completed U.S. Army Medical Research and Development Command 2016-12-31
NCT02406729 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine https://ClinicalTrials.gov/show/NCT02406729 Active, not recruiting Butantan Institute 2021-08-31
NCT02392325 Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults https://ClinicalTrials.gov/show/NCT02392325 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-07-31
NCT02332733 Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand https://ClinicalTrials.gov/show/NCT02332733 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-10-26
NCT02317900 Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults https://ClinicalTrials.gov/show/NCT02317900 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-11-30
NCT02302066 Safety and Immunogenicity of Different Schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants https://ClinicalTrials.gov/show/NCT02302066 Completed Takeda 2019-02-18
NCT02239614 TDENV PIV and LAV Dengue Prime-boost Strategy https://ClinicalTrials.gov/show/NCT02239614 Completed U.S. Army Medical Research and Development Command 2016-02-17
NCT02193087 Safety and Immunogenicity of Three Formulations of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) https://ClinicalTrials.gov/show/NCT02193087 Completed Takeda 2015-05-19
NCT01943825 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine https://ClinicalTrials.gov/show/NCT01943825 Completed Sanofi 2015-11-25
NCT01931176 Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT01931176 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2014-12-31
NCT01843621 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children https://ClinicalTrials.gov/show/NCT01843621 Completed U.S. Army Medical Research and Development Command 2005-02-28
NCT01728792 Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity https://ClinicalTrials.gov/show/NCT01728792 Completed Takeda 2013-11-01
NCT01702857 A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) https://ClinicalTrials.gov/show/NCT01702857 Completed U.S. Army Medical Research and Development Command 2017-01-20
NCT01696422 Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine https://ClinicalTrials.gov/show/NCT01696422 Active, not recruiting Butantan Institute 2016-04-30
NCT01666652 A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults https://ClinicalTrials.gov/show/NCT01666652 Completed U.S. Army Medical Research and Development Command 2015-09-30
NCT01619969 Celgosivir as a Treatment Against Dengue https://ClinicalTrials.gov/show/NCT01619969 Completed Singapore General Hospital 2013-03-31
NCT01601613 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever https://ClinicalTrials.gov/show/NCT01601613 Completed Novo Nordisk A/S 2002-11-30
NCT01550289 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India https://ClinicalTrials.gov/show/NCT01550289 Completed Sanofi 2013-12-31
NCT01542632 A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT01542632 Completed Takeda 2014-01-01
NCT01511250 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years https://ClinicalTrials.gov/show/NCT01511250 Completed Takeda 2016-04-01
NCT01506570 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine https://ClinicalTrials.gov/show/NCT01506570 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2013-09-30
NCT01502735 Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease https://ClinicalTrials.gov/show/NCT01502735 Completed U.S. Army Medical Research and Development Command 2013-09-30
NCT01502358 Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease https://ClinicalTrials.gov/show/NCT01502358 Completed U.S. Army Medical Research and Development Command 2013-12-31
NCT01488890 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine https://ClinicalTrials.gov/show/NCT01488890 Completed Sanofi 2013-09-27
NCT01477580 Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001) https://ClinicalTrials.gov/show/NCT01477580 Completed Merck Sharp & Dohme Corp. 2014-01-23
NCT01443247 Role of Andi-d in Dengue Fever: a Pilot Study https://ClinicalTrials.gov/show/NCT01443247 Completed Postgraduate Institute of Medical Education and Research 2011-09-30
NCT01436396 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT01436396 Completed Sanofi 2013-09-30
NCT01411241 Study of a Booster Injection of Pentaximâ„¢ Vaccine Administered With Dengue Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT01411241 Completed Sanofi 2014-02-04
NCT01391819 Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children https://ClinicalTrials.gov/show/NCT01391819 Completed GlaxoSmithKline 2015-01-30
NCT01374516 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America https://ClinicalTrials.gov/show/NCT01374516 Completed Sanofi 2014-11-30
NCT04133987 Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan https://ClinicalTrials.gov/show/NCT04133987 Recruiting National Taiwan University Hospital 2020-04-30
NCT04076254 Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever https://ClinicalTrials.gov/show/NCT04076254 Recruiting Indonesia University 2019-09-30
NCT04063774 Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia https://ClinicalTrials.gov/show/NCT04063774 Completed Universidad del Valle, Colombia 2018-07-15
NCT04035278 A Phase 1 Safety Study of Dengusiil in Healthy Adults https://ClinicalTrials.gov/show/NCT04035278 Recruiting Serum Institute of India Pvt. Ltd. 2020-12-30
NCT03999996 Long-Term Safety and Antibody Persistence of TDV and Impact of a Booster Dose https://ClinicalTrials.gov/show/NCT03999996 Active, not recruiting Takeda 2022-03-07
NCT03883620 Safety Study of Dengushield in Healthy Adults https://ClinicalTrials.gov/show/NCT03883620 Completed Serum Institute of India Pvt. Ltd. 2019-12-23
NCT03869060 Expansion of a Dengue-1 Live Virus Human Challenge https://ClinicalTrials.gov/show/NCT03869060 Completed State University of New York - Upstate Medical University 2019-09-20
NCT03831503 A Study of INO-A002 in Healthy Dengue Virus-naive Adults https://ClinicalTrials.gov/show/NCT03831503 Active, not recruiting University of Pennsylvania 2021-02-28
NCT03799237 Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquitoes https://ClinicalTrials.gov/show/NCT03799237 Recruiting University of Malaya 2020-03-31
NCT03771963 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults https://ClinicalTrials.gov/show/NCT03771963 Completed Takeda 2019-10-19
NCT03746015 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults https://ClinicalTrials.gov/show/NCT03746015 Active, not recruiting Takeda 2021-02-21
NCT02372175 Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain https://ClinicalTrials.gov/show/NCT02372175 Completed U.S. Army Medical Research and Development Command 2019-06-28
NCT03485144 A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan https://ClinicalTrials.gov/show/NCT03485144 Completed Medigen Vaccine Biologics Corp. 2019-05-10
NCT03432442 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients https://ClinicalTrials.gov/show/NCT03432442 Recruiting Mahidol University 2019-07-31
NCT03423173 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue https://ClinicalTrials.gov/show/NCT03423173 Completed Takeda 2018-07-20
NCT01224639 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever https://ClinicalTrials.gov/show/NCT01224639 Completed Takeda 2011-06-09
NCT03416036 Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge https://ClinicalTrials.gov/show/NCT03416036 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2019-01-17
NCT01254422 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia https://ClinicalTrials.gov/show/NCT01254422 Completed Sanofi 2012-09-28
NCT01187433 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America https://ClinicalTrials.gov/show/NCT01187433 Completed Sanofi 2012-10-31
NCT01134263 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia https://ClinicalTrials.gov/show/NCT01134263 Completed Sanofi 2012-11-30
NCT01096576 A Study of Balapiravir in Patients With Dengue Virus Infection https://ClinicalTrials.gov/show/NCT01096576 Completed Hoffmann-La Roche 2011-04-30
NCT01084291 Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine https://ClinicalTrials.gov/show/NCT01084291 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-05-31
NCT01073306 Safety and Immune Response to an Investigational Dengue Type 2 Vaccine https://ClinicalTrials.gov/show/NCT01073306 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-06-30
NCT01072786 Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine https://ClinicalTrials.gov/show/NCT01072786 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2012-06-30
NCT01064141 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines https://ClinicalTrials.gov/show/NCT01064141 Completed Sanofi 2012-09-30
NCT01110551 Tetravalent Chimeric Dengue Vaccine Trial https://ClinicalTrials.gov/show/NCT01110551 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2012-04-30
NCT01030211 Adult Dengue Platelet Study https://ClinicalTrials.gov/show/NCT01030211 Completed Tan Tock Seng Hospital 2014-12-31
NCT00993447 Immunogenicity and Safety of Sanofi Pasteur’s CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America https://ClinicalTrials.gov/show/NCT00993447 Completed Sanofi 2011-09-30
NCT00920517 Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine https://ClinicalTrials.gov/show/NCT00920517 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-01-31
NCT00919178 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus https://ClinicalTrials.gov/show/NCT00919178 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-05-31
NCT00883441 Implementation Research of New Dengue Vector Control Tools https://ClinicalTrials.gov/show/NCT00883441 Completed Institute of Tropical Medicine, Belgium 2009-02-28
NCT00880893 Study of Sanofi Pasteur’s CYD Dengue Vaccine in Healthy Subjects in Singapore https://ClinicalTrials.gov/show/NCT00880893 Completed Sanofi 2014-10-31
NCT00875524 Study of ChimeriVaxâ„¢ Tetravalent Dengue Vaccine in Healthy Subjects https://ClinicalTrials.gov/show/NCT00875524 Completed Sanofi 2014-08-31
NCT03612609 Pilot Study to Detect DENGUE Virus in Sperm https://ClinicalTrials.gov/show/NCT03612609 Completed University Hospital, Toulouse 2019-08-07
NCT03525119 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine https://ClinicalTrials.gov/show/NCT03525119 Completed Takeda 2018-12-28
NCT00936429 Study of HBV-001 D1 in Healthy Adults https://ClinicalTrials.gov/show/NCT00936429 Completed Hawaii Biotech, Inc. 2010-07-31
NCT02887482 Study of GLS-5700 in Dengue Virus Seropositive Adults https://ClinicalTrials.gov/show/NCT02887482 Completed GeneOne Life Science, Inc. 2017-10-31
NCT00842530 Efficacy and Safety of Dengue Vaccine in Healthy Children https://ClinicalTrials.gov/show/NCT00842530 Completed Sanofi 2013-09-30
NCT01436422 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine https://ClinicalTrials.gov/show/NCT01436422 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2014-03-31
NCT03342898 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults https://ClinicalTrials.gov/show/NCT03342898 Completed Takeda 2018-05-29
NCT03141138 Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine https://ClinicalTrials.gov/show/NCT03141138 Active, not recruiting U.S. Army Medical Research and Development Command 2020-06-30
NCT02425098 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore https://ClinicalTrials.gov/show/NCT02425098 Completed Takeda 2017-09-18
NCT01373281 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia https://ClinicalTrials.gov/show/NCT01373281 Completed Sanofi 2014-08-01
NCT00788151 Study of ChimeriVaxâ„¢ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years https://ClinicalTrials.gov/show/NCT00788151 Completed Sanofi 2010-02-16
NCT00740155 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults https://ClinicalTrials.gov/show/NCT00740155 Completed Sanofi 2009-10-31
NCT00730288 Study of ChimeriVaxâ„¢ Dengue Tetravalent Vaccine in Adult Subjects https://ClinicalTrials.gov/show/NCT00730288 Completed Sanofi 2007-08-31
NCT00712803 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3’Ddelta30) in Healthy Adults https://ClinicalTrials.gov/show/NCT00712803 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2009-09-30
NCT00617344 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US https://ClinicalTrials.gov/show/NCT00617344 Completed Sanofi 2009-12-31
NCT00473135 Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine https://ClinicalTrials.gov/show/NCT00473135 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-01-31
NCT00458120 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus https://ClinicalTrials.gov/show/NCT00458120 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-08-31
NCT00468858 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children https://ClinicalTrials.gov/show/NCT00468858 Completed U.S. Army Medical Research and Development Command 2010-04-30
NCT00384670 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children https://ClinicalTrials.gov/show/NCT00384670 Completed U.S. Army Medical Research and Development Command 2004-05-31
NCT00375726 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults https://ClinicalTrials.gov/show/NCT00375726 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-09-30
NCT00370682 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand https://ClinicalTrials.gov/show/NCT00370682 Completed U.S. Army Medical Research and Development Command 2008-02-29
NCT00350337 A Phase II Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults https://ClinicalTrials.gov/show/NCT00350337 Completed U.S. Army Medical Research and Development Command 2007-06-30
NCT00322946 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults https://ClinicalTrials.gov/show/NCT00322946 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2009-08-31
NCT00322049 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants https://ClinicalTrials.gov/show/NCT00322049 Completed U.S. Army Medical Research and Development Command 2009-06-30
NCT00290147 Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine https://ClinicalTrials.gov/show/NCT00290147 Completed U.S. Army Medical Research and Development Command 2006-12-31
NCT00270699 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults https://ClinicalTrials.gov/show/NCT00270699 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2009-12-31
NCT00239577 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults https://ClinicalTrials.gov/show/NCT00239577 Completed GlaxoSmithKline 2007-06-19
NCT00094705 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults https://ClinicalTrials.gov/show/NCT00094705 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2006-04-30
NCT00089908 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults https://ClinicalTrials.gov/show/NCT00089908 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2005-11-30
NCT00831012 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults https://ClinicalTrials.gov/show/NCT00831012 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2011-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT01550016 International Research Consortium on Dengue Risk Assessment, Management, and Surveillance https://ClinicalTrials.gov/show/NCT01550016 Completed University of Heidelberg Medical Center 2016-06-30
NCT00946218 Diagnosis and Characterization of Dengue Fever in Children https://ClinicalTrials.gov/show/NCT00946218 Completed St. Jude Children’s Research Hospital 2009-12-31
NCT02948933 Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine https://ClinicalTrials.gov/show/NCT02948933 Active, not recruiting Sanofi 2024-10-18
NCT02831699 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico https://ClinicalTrials.gov/show/NCT02831699 Completed Mexican Emerging Infectious Diseases Clinical Research Network 2019-01-25
NCT02827162 Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine https://ClinicalTrials.gov/show/NCT02827162 Completed Sanofi 2016-04-27
NCT02794181 Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD) https://ClinicalTrials.gov/show/NCT02794181 Completed National Institutes of Health Clinical Center (CC) 2019-03-14
NCT02510690 Factors Associated With Poor Dengue Outcomes in Malaysia https://ClinicalTrials.gov/show/NCT02510690 Completed Clinical Research Centre, Malaysia 2016-01-31
NCT02510638 The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia https://ClinicalTrials.gov/show/NCT02510638 Completed Clinical Research Centre, Malaysia 2015-12-31
NCT02305732 A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components https://ClinicalTrials.gov/show/NCT02305732 Completed Cerus Corporation 2016-05-31
NCT01293331 Study of Febrile Illness for Dengue-Endemic Areas in Latin America https://ClinicalTrials.gov/show/NCT01293331 Completed Sanofi 2011-12-31
NCT01983553 Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study https://ClinicalTrials.gov/show/NCT01983553 Completed Sanofi 2016-06-15
NCT01917422 Clinical Specimens Testing Program of Dengue Antigen Detection Reagents https://ClinicalTrials.gov/show/NCT01917422 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2013-06-30
NCT01702272 Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS https://ClinicalTrials.gov/show/NCT01702272 Completed Gen-Probe, Incorporated 2014-01-31
NCT01656174 Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross https://ClinicalTrials.gov/show/NCT01656174 Completed Gen-Probe, Incorporated 2014-12-31
NCT01477671 Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children https://ClinicalTrials.gov/show/NCT01477671 Completed Sanofi 2012-09-30
NCT01421732 Laboratory Diagnosis and Prognosis of Severe Dengue https://ClinicalTrials.gov/show/NCT01421732 Completed Oxford University Clinical Research Unit, Vietnam 2014-12-31
NCT03960385 Assessing the Effectiveness of Sanofi Pasteur’s Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil https://ClinicalTrials.gov/show/NCT03960385 Recruiting Albert B. Sabin Vaccine Institute 2020-03-31
NCT03632486 Bedside Ultrasound Predicts Progression of Severity of Disease in Dengue Fever https://ClinicalTrials.gov/show/NCT03632486 Completed University of Massachusetts, Worcester 2019-10-01
NCT03620487 Detection of Dengue Virus in Plasma of Patients in Nepal https://ClinicalTrials.gov/show/NCT03620487 Enrolling by invitation Karius, Inc. 2020-03-31
NCT03534245 Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children https://ClinicalTrials.gov/show/NCT03534245 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-09-30
NCT03465254 Dengue Serostatus Study in the Philippines https://ClinicalTrials.gov/show/NCT03465254 Active, not recruiting University of the Philippines 2022-10-31
NCT01226173 Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol https://ClinicalTrials.gov/show/NCT01226173 Completed Bio-Rad Laboratories 2012-08-31
NCT01218906 Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia https://ClinicalTrials.gov/show/NCT01218906 Completed Sanofi 2011-11-30
NCT01099852 Cohort of Patients Infected by an Arbovirus https://ClinicalTrials.gov/show/NCT01099852 Recruiting University Hospital Center of Martinique 2021-07-31
NCT04048837 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore https://ClinicalTrials.gov/show/NCT04048837 Completed National University Hospital, Singapore 2019-07-01
NCT03803618 Dengue Effectiveness Study in the Philippines https://ClinicalTrials.gov/show/NCT03803618 Recruiting University of the Philippines 2022-11-30
NCT00688389 Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection https://ClinicalTrials.gov/show/NCT00688389 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2020-12-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03206541 Neurologic Manifestations of the Arbovirus Infection in Colombia https://ClinicalTrials.gov/show/NCT03206541 Completed Johns Hopkins University 2019-12-31
NCT01868399 Pilot Survey of Dengue Fever in Solomon Islands https://ClinicalTrials.gov/show/NCT01868399 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2016-12-31
NCT03631719 Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia https://ClinicalTrials.gov/show/NCT03631719 Recruiting Universidad de Antioquia 2019-12-31